NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/22/2025
Back to search
Official data from USPTO
ROSLINCT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ROSLINCT
ST13
US500000097913008Class
35, 40, 41, 42, 44
Filing
97913008
Registration
7771028
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
04/23/2025
Trademark type
Word
Nice classes
35, 40, 41, 42, 44
Filing date
04/28/2023
Registration date
04/22/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/22/2025
Last transaction
04/23/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
08/04/2015
First use in commerce
05/06/2023
Drawing code
4
Owner type
99
Owner location
Edinburgh, GB
Examiner
WUDARSKY, MINDY
Law office
M80
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Roslin Cell Therapies Limited
Representatives
Benjamin P. Harbuck DENTONS US LLP
Technical classification
Nice Classes
Class 35Class 40Class 41Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 35
Business informationconsultancy and management services in the fields of designingbuildingtesting and validating processes and systems for use in cell therapy and gene therapy services; business consultation services in the nature of technology transfer advice and management in the fields of cell therapy and gene therapy; advertisingmarketing and promotional services in the fields of cell therapy and gene therapy; informationadvisory and consultancy services related to the aforesaid
Class 40
Contract manufacturing of pharmaceutical and biopharmaceutical products in the fields of cell therapy and gene therapy; contract manufacturing in the fields of cell therapy and gene therapy; custom manufacturing of pharmaceutical and biopharmaceutical products in the fields of cell therapy and gene therapy; custom manufacturing in the fields of cell therapy and gene therapy; custom fabrication and production of cells for others; manufacturing process consulting in the fields of cell therapy and gene therapy; informationadvisory and consultancy services related to the aforesaid
Class 41
Education and training servicesclassesseminarstutorialsconferences and workshops in the fields of cell therapy and gene therapy; provision of online educationtraining and teaching servicesclassesnon-downloadable webinars and tutorials in the fields of cell therapy and gene therapy; arrangingorganising and conducting of colloquiumsconferencescongressesseminars and symposiums in the fields of cell therapy and gene therapy; publication of booksscientific papers and texts in the fields of cell therapy and gene therapy; informationadvisory and consultancy services related to the aforesaid
Class 42
Scientific researchdevelopment and testing services in the fields of cell therapy and gene therapy; research and development of new products for others in the fields of cell therapy and gene therapy; pharmaceutical and biopharmaceutical research and development services in the fields of cell therapy and gene therapy; scientific consultancy services in the fields of designingbuildingtesting and validating processes and systems for use in cell therapy and gene therapy services; design and development of computer hardware and software in the biopharmaceuticalcell therapy and gene therapy fields; development of computer databases in the biopharmaceuticalcell therapy and gene therapy fields; scientific development of custom assays for cell therapy and gene therapy; stem cell research services; informationadvisory and consultancy services related to the aforesaid
Class 44
Medical services relating to the removaltreatment and processing of stem cells; medical servicesstem cell therapy services; medical servicesgene therapy services; stem cell bank servicesstem cell storage; informationadvisory and consultancy services related to the aforesaid
Publications
History of USPTO decisions and trademark events.
22 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
04/22/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
04/02/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
04/02/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
03/14/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/13/2025
IUAF
USE AMENDMENT FILED
01/09/2025
EISU
TEAS STATEMENT OF USE RECEIVED
01/09/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/09/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/14/2024
PUBO
PUBLISHED FOR OPPOSITION
05/14/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/24/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/05/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/02/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/02/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/02/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/30/2024
GNRT
NON-FINAL ACTION E-MAILED
01/30/2024
CNRT
NON-FINAL ACTION WRITTEN
01/30/2024
DOCK
ASSIGNED TO EXAMINER
01/25/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/27/2023
NWAP
NEW APPLICATION ENTERED
05/02/2023
Continuous trademark protection
Get notified about every new filing that threatens ROSLINCT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.